Several widely prescribed medications can increase your risk of gallstones, biliary sludge, or gallbladder inflammation. The most well-documented offenders include certain cholesterol-lowering drugs, hormonal therapies, GLP-1 weight loss medications, specific antibiotics, and a few less obvious categories like blood pressure medications. The risk varies significantly depending on the drug, the dose, and how long you take it.
GLP-1 Weight Loss and Diabetes Medications
Drugs like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) have become some of the most commonly discussed medications linked to gallbladder problems. Overall, GLP-1 drugs are associated with a 37% increased risk of gallbladder and biliary diseases compared to other treatments. The risk breaks down further: a 27% increase for gallstones, a 36% increase for gallbladder inflammation, and a 55% increase for broader biliary disease.
The risk climbs with higher doses and longer treatment. In weight loss trials specifically, the risk more than doubled compared to placebo. People over 60 and women face the highest risk, and problems tend to appear after about 120 days of use. Liraglutide and semaglutide carry the strongest associations among the GLP-1 drugs, while dulaglutide appears to carry a weaker link.
The mechanism involves two problems at once. These drugs slow gallbladder emptying, allowing bile to sit and thicken. They also disrupt the normal hormonal signals that regulate bile acid balance and gallbladder contraction after meals. Rapid weight loss itself is a known gallstone trigger, so patients losing significant weight on these medications face a compounding effect.
Estrogen and Hormonal Therapies
Estrogen is one of the oldest known medication-related risk factors for gallbladder disease. In the Women’s Health Initiative trials, women taking hormone replacement therapy had roughly 60 to 67% higher rates of gallbladder disease or gallbladder surgery compared to those on placebo. Observational studies suggest the risk can be as high as 2.5 times that of non-users.
Estrogen increases cholesterol secretion into bile, making the bile more saturated and prone to forming stones. This applies to both oral hormone replacement therapy and oral contraceptives containing estrogen, though the risk appears higher with hormone replacement doses. Transdermal (patch) forms of estrogen may carry a lower risk because they bypass the liver’s first-pass metabolism, but this hasn’t been as thoroughly studied.
Fibrates for High Cholesterol
Fibrate drugs like gemfibrozil and clofibrate directly change the composition of bile in ways that promote stone formation. In studies, gemfibrozil increased the amount of cholesterol secreted into bile from 47 to 70 milligrams per hour while simultaneously decreasing bile acid output from 943 to 694 milligrams per hour. Bile acids normally keep cholesterol dissolved in bile, so less bile acid plus more cholesterol creates a recipe for crystallization.
The overall risk of gallstones with fibrates is estimated at under 1%, which sounds small but is significant given how many people take these drugs. Clofibrate was the first fibrate clearly linked to gallstones, and gemfibrozil appears to carry a similar mechanism. If you’re on a fibrate and have other gallstone risk factors (obesity, rapid weight loss, family history), this is worth discussing with your prescriber.
Statins: A Different Story
Interestingly, statins appear to do the opposite of fibrates. A meta-analysis of over 590,000 patients found that long-term statin use reduced gallstone risk by 27%. Medium-term use lowered risk by about 14%. There’s one catch: short-term statin use (under a year) was actually associated with a 16 to 20% higher risk of gallstones. The protective effect only kicks in with continued use beyond a year. Statins lower cholesterol in bile just as they lower it in blood, which over time makes gallstone formation less likely.
Ceftriaxone (a Common Antibiotic)
Ceftriaxone stands out among antibiotics for its ability to cause biliary sludge and pseudolithiasis, a condition where calcium salts of the drug precipitate directly in the gallbladder. This happens in 15 to 46% of children treated with the drug, a remarkably high rate. Problems can appear as quickly as 35 hours after starting treatment, though most cases show up between 4 and 11 days in.
Symptoms typically include abdominal pain, fever, and vomiting, usually appearing between the fourth and seventh day of treatment. The good news is that ceftriaxone-related sludge almost always resolves on its own after the drug is stopped, which is why it’s called “pseudolithiasis” rather than true gallstone disease. Ultrasound typically detects the sludge within 10 to 20 days of starting treatment. While most of the research focuses on children (who receive ceftriaxone frequently for infections), the same effect can occur in adults.
Octreotide and Somatostatin Analogs
Octreotide, used primarily to treat acromegaly and certain hormone-secreting tumors, carries one of the highest gallstone rates of any medication. In one study of patients with acromegaly, 34% of those treated with octreotide for an average of 20 months developed gallstones, compared to 16% of untreated patients. The drug significantly impairs gallbladder emptying, increasing the volume of bile that remains in the gallbladder after meals. Stagnant bile concentrates and forms stones over time. For patients who need long-term octreotide therapy, periodic ultrasound monitoring of the gallbladder is standard practice.
Thiazide Diuretics
Thiazide diuretics, commonly prescribed for high blood pressure, have a more modest but real association with gallbladder disease. In a study following over 81,000 women for 20 years, current thiazide users had a 39% higher rate of gallbladder surgery compared to women who never used thiazides. Past users still had a 16% elevated risk. The mechanism isn’t fully understood, and researchers note it’s difficult to completely separate the effect of the drug from the underlying conditions it treats. Still, the association has been consistent across multiple studies.
How These Medications Cause Problems
Medication-related gallbladder problems generally work through one of two pathways. Some drugs change bile composition, making it more saturated with cholesterol and more likely to form crystals. Fibrates and estrogen fall into this category. Other drugs impair gallbladder motility, meaning the gallbladder doesn’t contract and empty properly after meals. Octreotide and GLP-1 drugs work primarily through this mechanism. Some medications, like ceftriaxone, take a third route entirely by precipitating directly in bile as insoluble salts.
The timeline for problems varies widely. Ceftriaxone can cause sludge within days. GLP-1 drugs typically cause issues after about four months. Estrogen and fibrates may take months to years, as cholesterol-saturated bile gradually forms stones. Drug-related gallbladder injury generally falls within 5 days to 3 months of starting a medication, though some drugs cause problems only after prolonged use.
Who Faces the Highest Risk
Medications don’t cause gallbladder disease in a vacuum. Your baseline risk matters enormously. Women are already two to three times more likely to develop gallstones than men, so adding estrogen or a GLP-1 drug compounds an existing vulnerability. Obesity, rapid weight loss (more than 1.5 pounds per week), a family history of gallstones, and age over 40 all raise your starting risk. If you’re taking one of these medications and already have multiple risk factors, the combined probability of gallbladder problems rises meaningfully.
If you’re experiencing right-sided upper abdominal pain, pain after fatty meals, nausea, or bloating while taking any of these medications, bring it up with your prescriber. Many drug-related gallbladder problems are reversible if caught early, particularly those caused by ceftriaxone or GLP-1 drugs. Others, like fibrate-related or estrogen-related gallstones, may require the same management as any other gallstones once they’ve formed.